Apogee Therapeutics (APGE) Cash from Investing Activities (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Cash from Investing Activities data on file, last reported at -$35.3 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$35.3 million, down 372.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$227.9 million (up 3.32% YoY), and the FY2025 annual result was -$179.6 million, up 40.23% from the prior year.
• Cash from Investing Activities grew to -$35.3 million in Q1 2026 per APGE's latest filing, from -$288.6 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $78.1 million in Q2 2025 and troughed at -$288.6 million in Q4 2025.
• A 4-year average of -$55.5 million and a median of -$37.5 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities surged 216.82% in 2024, then slumped 722.48% in 2025.
• A 4-year view of Cash from Investing Activities shows it stood at -$39.7 million in 2023, then surged by 216.82% to $46.4 million in 2024, then slumped by 722.48% to -$288.6 million in 2025, then soared by 87.75% to -$35.3 million in 2026.
• Business Quant data shows APGE's Cash from Investing Activities at -$35.3 million in Q1 2026, -$288.6 million in Q4 2025, and $17.9 million in Q3 2025.